CN108077675A - A kind of fruit drink for being used to prevent nonalcoholic fatty liver - Google Patents
A kind of fruit drink for being used to prevent nonalcoholic fatty liver Download PDFInfo
- Publication number
- CN108077675A CN108077675A CN201711402942.2A CN201711402942A CN108077675A CN 108077675 A CN108077675 A CN 108077675A CN 201711402942 A CN201711402942 A CN 201711402942A CN 108077675 A CN108077675 A CN 108077675A
- Authority
- CN
- China
- Prior art keywords
- powder
- fruit drink
- lactobacillus
- fruit
- fatty liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 47
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 57
- 239000006041 probiotic Substances 0.000 claims abstract description 24
- 235000018291 probiotics Nutrition 0.000 claims abstract description 24
- 241000219357 Cactaceae Species 0.000 claims abstract description 11
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 11
- 230000000529 probiotic effect Effects 0.000 claims abstract description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 5
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 5
- 235000015197 apple juice Nutrition 0.000 claims abstract description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 5
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 5
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 5
- 235000015203 fruit juice Nutrition 0.000 claims description 8
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 5
- 241001608472 Bifidobacterium longum Species 0.000 claims description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 5
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 5
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 5
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 5
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 5
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 5
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 5
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 240000006024 Lactobacillus plantarum Species 0.000 claims 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims 2
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 26
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 16
- 208000004930 Fatty Liver Diseases 0.000 abstract description 13
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 13
- 208000010706 fatty liver disease Diseases 0.000 abstract description 13
- 150000002632 lipids Chemical class 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 8
- 235000009200 high fat diet Nutrition 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000003902 lesion Effects 0.000 abstract description 4
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 108010028554 LDL Cholesterol Proteins 0.000 description 10
- 150000003626 triacylglycerols Chemical class 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- 102100038495 Bile acid receptor Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000007863 steatosis Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100102907 Mus musculus Wdtc1 gene Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 101150096914 mttp gene Proteins 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 101000800132 Mus musculus Thyroglobulin Proteins 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of for preventing the fruit drink of nonalcoholic fatty liver, in terms of 1L fruit drinks, the composition of the fruit drink includes：80~120mL of Cactus juice, 150~250mL of fresh apple juice, 0.5~1.5 gram of maltodextrin, 1~3 gram of oligofructose, 1~3 gram of galactooligosaccharide, 4~6 grams of probiotic powder, surplus is water；The number of live bacteria of probiotics included in every liter of fruit drink is 0.8 × 1011~4.5 × 1011CFU.The fruit drink can effectively participate in organismic internal environment lipid-metabolism, the preventative occurrence and development for alleviating NAFLD, it is by improving lipid metaboli so as to prophylactically mitigate liver fat degree, there is good prevention effect to fatty live lesions, TG, TC and LDL C are horizontal caused by the fruit drink can reduce high fat diet simultaneously, and HDL C concentration is improved, inhibit fat and store up, there is apparent inhibitory action to fatty liver.
Description
Technical field
The present invention relates to a kind of drinks, are specifically a kind of fruit drink for being used to prevent nonalcoholic fatty liver.
Background technology
Recently as occurred frequently, the morbidity of non-alcohol fatty liver (NAFLD) of fat, hyperlipidemia and diabetes
Rate constantly raises and morbidity tends to rejuvenation.The generation of non-alcohol fatty liver and glucose -lipid metabolism disorder are closely related.With
The fashion trend of fat and its associated metabolic syndrome globalization, non-alcohol fatty liver has become the prosperities such as America and Europe
Country and the Important cause of disease of China areas of well-being chronic liver disease.Non-alcohol fatty liver, which removes, can directly result in Decompensated stage liver
Hardening, hepatocellular carcinoma and liver transplantation recurrence are outer, can also influence the progress of other chronic liver diseases, and participate in diabetes B and artery
The morbidity of atherosis.Metabolic syndrome associated malignancies, arteriosclerotic cardiovascular and cerebrovascular disease and hepatic sclerosis are to influence
An important factor for patients with nonalcoholic fatty liver disease quality of life and life expectancy.At present, to obesity, hyperlipidemia, glycosuria
For the patient of disease, the non-drug measure such as adjustment diet and increase movement is to prevent the main path of fatty liver, but for life
Movable joint is played for the modern generally accelerated, these measures are difficult to realize, and the risk of fatty liver recurrence is larger.Therefore, visit
Solution of the rope based on lipid metaboli source is the feasible program of current prevention non-alcoholic fatty liver disease, in consideration of it, of the invention
It is proposed a kind of fruit drink for being used to prevent nonalcoholic fatty liver.
The content of the invention
The technical problems to be solved by the invention are：In view of the deficiencies of the prior art, one kind is provided for preventing non-alcohol
Property fatty liver fruit drink, the fruit drink can by improve lipid metaboli so as to prophylactically mitigate liver fat degree,
There is good prevention effect to fatty live lesions, while the fruit drink can reduce triglycerides caused by high fat diet
(TG), T-CHOL (TC) and low density lipoprotein cholesterol (LDL-C) are horizontal, and improve serum High Density Lipoprotein Cholesterol
(HDL-C) concentration, inhibits fat and stores up, and has apparent inhibitory action to fatty liver.
Technical solution is used by the present invention solves above-mentioned technical problem：It is a kind of to be used to prevent nonalcoholic fatty liver
Fruit drink, in terms of 1L fruit drinks, the composition of the fruit drink includes：80~120mL of Cactus juice, fresh apple juice
150~250mL, 0.5~1.5 gram of maltodextrin, 1~3 gram of oligofructose, 1~3 gram of galactooligosaccharide, 4~6 grams of probiotic powder,
Surplus is water；The number of live bacteria of probiotics included in every liter of fruit drink is 0.8 × 1011~4.5 × 1011CFU。
Cactus fruit can reduce low-density lipoprotein synthesis level, reducing oxidation should by increasing fatty acid oxidation
Swash and improve the approach of insulin secretion to mitigate fatty liver.On the other hand, probiotics can by improving enteron aisle ecological environment,
Recover intestinal flora, reducing intestinal permeability etc. to improve host's microecological balance, while also have increases aliphatic acid oxygen
Change and the effect of insulin sensitivity enhancing.There are the micro- raw floras of a large amount of enteron aisles in human intestine to safeguard host's microecological balance, multinomial to grind
Study carefully and support that the change of intestinal flora is related with the generation of fat, NAFLD and its complication, process may relate to improve lipid generation
It thanks, adjust intestinal flora, improving gut epithelium barrier function and reduce the mechanism such as inflammatory reaction.
Preferably, the probiotic powder is bifidobacterium lactis powder, lactobacillus acidophilus powder, Lactobacillus rhamnosus powder, dry
Lactobacillus paracasei powder, bifidobacterium longum powder, lactobacillus reuteri powder, thermophilus bacterium powder, lactobacillus bulgaricus powder and plant breast
Two or more composition in bacillus powder.
Further, in terms of 1L fruit drinks, the viable count of each probiotics is 2 × 1010~5 × 1010CFU。
Further, the probiotic powder be bifidobacterium lactis powder, it is lactobacillus acidophilus powder, Lactobacillus rhamnosus powder, dry
Lactobacillus paracasei powder, bifidobacterium longum powder, lactobacillus reuteri powder, thermophilus bacterium powder, lactobacillus bulgaricus powder and plant breast
The composition of bacillus powder, in terms of 1L fruit drinks, the viable count of each probiotics is 2 × 1010~3.5 × 1010CFU。
Compared with prior art, the advantage of the invention is that：One kind provided by the invention is used to prevent non-alcoholic fatty
The fruit drink of liver contains Cactus juice, fresh apple juice, maltodextrin, oligofructose, galactooligosaccharide and probiotics
Powder, the fruit drink can effectively participate in organismic internal environment lipid-metabolism, be combined by diet such as cactus fruit and probiotics,
Its fat reducing, synergistic effect that is anti-inflammatory and increasing intestinal microbiota are played, with the occurrence and development of preventative alleviation NAFLD.This
Invention fruit drink can have very fatty live lesions by improving lipid metaboli so as to prophylactically mitigate liver fat degree
Good prevention effect, at the same triglycerides (TG) caused by the fruit drink can reduce high fat diet, T-CHOL (TC) with it is low
Density lipoprotein-cholesterol (LDL-C) is horizontal, and improves serum High Density Lipoprotein Cholesterol (HDL-C) concentration, inhibits fat
It stores up, there is apparent inhibitory action to fatty liver.
Description of the drawings
Fig. 1 is the liver fatization histopathological findings (× 100) of blank control group (CK groups) mouse；
Fig. 2 is the liver fatization histopathological findings (× 100) of model group (M groups) mouse；
Fig. 3 is the liver fatization histopathological findings (× 100) of fruit juice group (OL groups) mouse.
Specific embodiment
The present invention is described in further detail below in conjunction with attached drawing embodiment.
The fruit drink for being used to prevent nonalcoholic fatty liver of embodiment, in terms of 1L fruit drinks, the fruit drink
Composition includes：Cactus juice 100mL, fresh apple juice 200mL, 1 gram of maltodextrin, 2 grams of oligofructose, galactooligosaccharide 2
Gram, 4 grams of probiotic powder and water 700mL, wherein, probiotic powder is bifidobacterium lactis powder, lactobacillus acidophilus powder, Lactobacillus rhamnosus
Powder, Lactobacillus casei powder, bifidobacterium longum powder, lactobacillus reuteri powder, thermophilus bacterium powder, lactobacillus bulgaricus powder and plant
The composition of object lactobacillus powder, the viable count of each probiotics included in every liter of fruit drink is 2 × 1010CFU, i.e. every liter of fruit
The number of live bacteria of probiotics included in juice beverage is 1.8 × 1011CFU。
The effect for preventing the fruit drink of embodiment nonalcoholic fatty liver by zoopery carries out experimental verification：
8 week old SPF grades of mouse (C57BL/6) 24 of healthy male that selection is provided by Hangzhou Si Laike animals company, 24
Experiment mice adapts to after a week, be randomly divided into three groups in animal center：Blank control group (CK, control check), model
Group (M, model group), fruit juice group (OL, opuntia sficus-indica and lactic acid bacteria-
diet group).No difference of science of statistics (P between three groups of mouse weights>0.05), every group of every mouse ear edge punching is as mark
Note.Blank control group is fed using basal diet, model group uses High-fat diet, and fruit juice group uses high fat diet and reality
The fruit drink for applying example is fed, and the nursing time of three groups of mouse is 11 weeks.
Probiotic powder used is stored in 4 DEG C of refrigerating chambers in dry powder form in advance in the juice beverage prescription of fruit juice group feeding
It is interior, it is now with the current；Cactus juice is obtained by filtration after being squeezed the juice by the cactus fruit in the Sanya place of production, and Cactus juice is placed in refrigerator
In save backup；The current fresh squeezing of cider.
Feed needed for three groups of mouse nursings is provided by animal center, and all feeds preserve in a dry form.Blank control
Group feeding conventional foundation feed (10%kcal, 3.85kcal g-1, Research Diets, Inc., New Brunswick,
NJ, USA), model group and fruit juice group are fed with high lipid food (60%kcal, 5.24kcal g-1), and fruit juice group mouse is supplying
While to high lipid food distinguish gavage prepare embodiment fruit drink (0.2mL, 108CFU/ pcs/day).Mouse freely drinks
Water is ingested, daily to replace drinking-water and feed, is modeled 11 weeks.Record mouse weight, average daily food ration are weighed weekly.To institute after 11 weeks
There is group mouse to weigh after carrying out anaesthetized with pentobarbital (150uL/ is only), measurement Mice Body is grown to calculate mouse adipose coefficient
(FC).It is dissected after all mouse anesthesias, row cardiocentesis collects painstaking effort and prepares serum in 3mL centrifuge tubes, for biochemical indicator
Measure.Mouse peritoneal is opened, hepatomegaly leaf is taken to be used to prepare hepatic pathology section after fixing hepatomegaly leaf with formalin.Take kidney
Week, testis week, groin are subcutaneous, fat weighs collect after record respectively after mesenterium and omoplate.The blood sample equal 37 of all acquisitions
DEG C stand 1h after centrifuge (8000rpm, 10min), take supernatant.Row is examined after the mice serum of collection is placed in -24 DEG C of refrigerator cold-storages
It surveys.All fixed tissue samples of liquid nitrogen are placed in -70 DEG C of storages for sample analysis.All operations meet animal welfare simultaneously
Pass through Ethic review.
The following detection and analysis are carried out after modeling：
1st, experimental method
Biochemical Indices In Serum detects：Mouse TG, TC, HDL-C and LDL-C level is detected with ELISA kit.
Fat coefficient calculates：It is calculated with FC/%=(interior fat gross mass/mouse quality) × 100% formula.
Liver fatization histologic analysis：Liver section, 4 μ m-thicks, with hematoxylin eosin staining.Liver morphology is analyzed
It is carried out by the microscopic analysis of Leica-QWin image analyzer systems.
Data processing：Variance analysis for the body weight increase between three groups of mouse and food ration, Biochemical Indices In Serum and
FC difference tests.NAS sxemiquantitative scores to evaluate hepatic tissue denaturation degrees.All data and chart processing are in SPSS18.0
It is carried out on software.
2nd, average daily food ration and body weight increase amount
Average daily food ration the results of analysis of variance shows CK groups>OL groups>M groups, CK groups with other two groups there are significant difference (P
≤ 0.05), normally group control Food intake is maximum.Body weight increase amount the results of analysis of variance shows M groups>OL groups>CK groups.
3rd, liver fatization histopathology
Hepatic tissue pathology is analyzed and NAS scorings show that the lobuli hepatis structure of CK group mouse is clear, hepatic cell cords marshalling,
Sinus hepaticus is normal.Have no necrosis, steatosis and cell infiltration.Liver fatization histopathological findings such as Fig. 1 of CK group mouse
It is shown.NAS scorings are 1.0 ± 1.0.
The notable hydropic degeneration of M group mouse liver cells, lobe of the liver most cells steatosis are become with the fat around central vein
Cell is more, and fat drips are larger, and liver rope is disorderly, and sinus hepaticus is narrow, partially visible a small amount of inflammatory cell infiltration.The liver fat of M group mouse
Fat histopathological findings are as shown in Figure 2.NAS scorings are 4.2 ± 2.1, show that nonalcoholic fatty liver mouse model models
Success.
OL groups majority lobuli hepatis structure is clear, hepatic cell cords marshalling, and sinus hepaticus is normal.Have no necrosis, steatosis and
Cell infiltration；Occur intensive small fat drips, and visible cell oedema in a small number of liver cells.The liver fatization tissue disease of OL group mouse
It is of science that the results are shown in Figure 3.NAS scorings 1.6 ± 0.9.
4th, serum biochemistry variable
Serum TG levels the results of analysis of variance is shown：M groups>CK groups>OL groups (P≤0.05).The horizontal results of mice serum TC
Display：M groups>OL groups>CK groups (P≤0.05).The horizontal the results shows of mice serum LDL-C：M groups>OL groups>CK groups.Mice serum
The horizontal the results shows of HDL-C：CK groups>OL groups>M groups.
5th, fat coefficient result
FC the results of analysis of variance shows M groups>OL groups>CK groups, and CK groups with another two groups there are significant difference (P≤
0.05)。
Above average daily food ration, body weight increase amount, serum TG levels, serum TC are horizontal, Serum HDL-C level, serum
LDL-C is horizontal and FC the results are shown in Table 1.
1 analysis of variance table of table
Note：*P<0.05
To sum up, it is identical in the basal diet structure of model group (M groups) and fruit juice group (OL groups) using CK groups as control
(P on the premise of (average daily food ration)>0.05), OL groups mouse fatty liver pathology damage is substantially lighter than M groups, mouse fatty degeneration of liver
Degree and scoring are below M groups, and it is pre- well to show that fruit drink of the present invention has fatty live lesions caused by feeding high in fat
Anti- effect.
On the basis of M groups show fatty degeneration of liver pathology, OL groups mouse fatty degeneration of liver degree and scoring are significantly lower than M
Group.OL group mouse adipose coefficients (FC) are less than M groups, and serum High Density Lipoprotein Cholesterol (HDL-C) is horizontal higher than M groups, and blood
Clear T-CHOL (TC), oily three esters (TG) and low density lipoprotein cholesterol (LDL-C) level are below M groups.Should the result shows that
TG, TC and LDL-C caused by fruit drink of the present invention can reduce high fat diet are horizontal, and improve Serum HDL-C concentration, inhibit fat
Fat stores up, and has apparent inhibitory action to fatty liver.
Fruit drink of the present invention improves mouse lipid-metabolism and is related to following mechanism：
(1) body lipid level is reduced.It is related to enteric microorganism to adjust choline and bile acid.Choline has affinity to fat
Power and emulsification property can promote fat that cholesterol deposition is exported, prevented and removed by liver.Core Farnesoid X receptor (FXR) is expressed
In liver and enteron aisle, bile acid can activate FXR and g protein coupled receptor (TGR5), flowed down and believed by signal identification effect activation
Number, in control liver lipids generation.TGR5 combinations secondary bile acid by stimulate glucagon-like-peptide-1 (GLP-1) secrete,
Promote the dynamic equilibrium of glucose metabolism.It can relate to inhibit cholesterol generation and reabsorption in addition, probiotics reduces lipid level,
Promoting the intestines liver Xun Huan of cholesterol excretion and interference cholate increases the processes such as the consumption of body cholesterol.
(2) intestine microenvironment is improved.NAFLD patient there are intestinal permeability increase and intestinal microflora increase or
Person, which forms, to be changed.Probiotics generate metabolite, to opportunist generate antibacterial or bactericidal effect, reduce enteron aisle pH value into
And inhibit the growth and breeding of pathogenic bacteria.Therefore, HypercholesterolemicRats can be improved by adding the diet of probiotics, safeguard gut barrier
Integrality, the dynamic equilibrium of raw system micro- to host enteron aisle and the prevention of NAFLD are most important.
Fruit drink of the present invention can obviously improve serum triglyceride (TG) level, reduces serum LDL and improves HDL water
Flat, mechanism is related to：
(1) experiment mice it is adipohepatic mitigate with high serum-concentration adiponectin and with fatty acid oxidation, fat
Matter transport, the mRNA (Mttp mRNA) of microsomal triglyceride transporter related gene are significantly reduced.Adiponectin is a kind of anti-
Scorching Adipocyte Factor can be accumulated by activating PPAR α with limiting fat in liver.
(2) effective polyphenol kaempferol ingredient in cactus fruit has antioxidation activity.Oxidative stress is secreted in LDL
Occupy key player in adjusting, peroxidatic reaction of lipid mediates the hydrolysis of Apolipoprotein B-100, and oxidative stress reduces Mttp
The expression of mRNA and the secretion of very low density lipoprotein (VLDL).
Claims (4)
1. a kind of fruit drink for being used to prevent nonalcoholic fatty liver, which is characterized in that in terms of 1L fruit drinks, the fruit juice beverage
The composition of material includes：It is 80~120mL of Cactus juice, 150~250mL of fresh apple juice, 0.5~1.5 gram of maltodextrin, oligomeric
1~3 gram of fructose, 1~3 gram of galactooligosaccharide, 4~6 grams of probiotic powder, surplus is water；What is included in every liter of fruit drink is prebiotic
Bacterium viable count is 0.8 × 1011~4.5 × 1011 CFU。
2. a kind of fruit drink for being used to prevent nonalcoholic fatty liver according to claim 1, which is characterized in that described
Probiotic powder for bifidobacterium lactis powder, lactobacillus acidophilus powder, Lactobacillus rhamnosus powder, Lactobacillus casei powder, bifidobacterium longum
Two kinds or two kinds in powder, lactobacillus reuteri powder, thermophilus bacterium powder, lactobacillus bulgaricus powder and lactobacillus plantarum powder with
On composition.
3. a kind of fruit drink for being used to prevent nonalcoholic fatty liver according to claim 2, which is characterized in that with 1L
Fruit drink meter, the viable count of each probiotics is 2 × 1010~5 × 1010 CFU。
4. a kind of fruit drink for being used to prevent nonalcoholic fatty liver according to claim 2, which is characterized in that described
Probiotic powder for bifidobacterium lactis powder, lactobacillus acidophilus powder, Lactobacillus rhamnosus powder, Lactobacillus casei powder, bifidobacterium longum
Powder, lactobacillus reuteri powder, thermophilus bacterium powder, the composition of lactobacillus bulgaricus powder and lactobacillus plantarum powder, with 1L fruits
Juice beverage meter, the viable count of each probiotics is 2 × 1010~3.5 × 1010 CFU。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711402942.2A CN108077675A (en) | 2017-12-22 | 2017-12-22 | A kind of fruit drink for being used to prevent nonalcoholic fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711402942.2A CN108077675A (en) | 2017-12-22 | 2017-12-22 | A kind of fruit drink for being used to prevent nonalcoholic fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108077675A true CN108077675A (en) | 2018-05-29 |
Family
ID=62178401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711402942.2A Pending CN108077675A (en) | 2017-12-22 | 2017-12-22 | A kind of fruit drink for being used to prevent nonalcoholic fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108077675A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108641988A (en) * | 2018-06-15 | 2018-10-12 | 吉林省农业科学院 | Lactobacillus plantarum NA136 and its application in alleviating non-alcoholic fatty liver disease |
| CN114145461A (en) * | 2021-11-26 | 2022-03-08 | 广州能靓生物技术有限公司 | Probiotics composition for relieving non-alcoholic fatty liver |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104872283A (en) * | 2015-06-16 | 2015-09-02 | 河北经贸大学 | Cactus polysaccharide yogurt and preparation method thereof |
| CN105395468A (en) * | 2015-12-25 | 2016-03-16 | 北京工商大学 | Cactus fermented raw stock and preparation method and application thereof |
| CN106261362A (en) * | 2016-08-08 | 2017-01-04 | 南昌大学 | A kind of honeysuckle composition beverage with the liver protecting effect and preparation method |
-
2017
- 2017-12-22 CN CN201711402942.2A patent/CN108077675A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104872283A (en) * | 2015-06-16 | 2015-09-02 | 河北经贸大学 | Cactus polysaccharide yogurt and preparation method thereof |
| CN105395468A (en) * | 2015-12-25 | 2016-03-16 | 北京工商大学 | Cactus fermented raw stock and preparation method and application thereof |
| CN106261362A (en) * | 2016-08-08 | 2017-01-04 | 南昌大学 | A kind of honeysuckle composition beverage with the liver protecting effect and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 喻宁华: "仙人掌多糖对小鼠急性肝损伤的保护作用", 《中国优秀硕士学位论文全文数据库（电子期刊） 医药卫生科技辑》 * |
| 陈默等: "肠道菌群与非酒精性脂肪肝相关性的研究进展", 《中国微生态学杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108641988A (en) * | 2018-06-15 | 2018-10-12 | 吉林省农业科学院 | Lactobacillus plantarum NA136 and its application in alleviating non-alcoholic fatty liver disease |
| CN108641988B (en) * | 2018-06-15 | 2021-09-21 | 吉林省农业科学院 | Lactobacillus plantarum NA136 and application thereof in relieving non-alcoholic fatty liver disease |
| CN114145461A (en) * | 2021-11-26 | 2022-03-08 | 广州能靓生物技术有限公司 | Probiotics composition for relieving non-alcoholic fatty liver |
| CN114145461B (en) * | 2021-11-26 | 2023-10-31 | 广州能靓生物技术有限公司 | Probiotic composition for relieving nonalcoholic fatty liver |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ding et al. | Screening for lactic acid bacteria in traditional fermented Tibetan yak milk and evaluating their probiotic and cholesterol-lowering potentials in rats fed a high-cholesterol diet | |
| Safavi et al. | The effects of synbiotic supplementation on some cardio-metabolic risk factors in overweight and obese children: a randomized triple-masked controlled trial | |
| Karimi et al. | The anti-obesity effects of Lactobacillus casei strain Shirota versus Orlistat on high fat diet-induced obese rats | |
| Anandharaj et al. | Effects of probiotics, prebiotics, and synbiotics on hypercholesterolemia: a review | |
| Gobbetti et al. | Functional microorganisms for functional food quality | |
| US9113641B2 (en) | Probiotic bacteria and regulation of fat storage | |
| EP2615163B1 (en) | Composition comprising probiotics having aryl hydrocarbon receptor activating potency for use as anti-inflammatory agents | |
| US10543239B2 (en) | Lactic acid bacteria and bifidobacteria for treating endotoxemia | |
| CN103314099B (en) | Lactic bacterium having an effect of ameliorating metabolic syndrome | |
| Mojikon et al. | Probiotication of nutritious fruit and vegetable juices: an alternative to dairy-based probiotic functional products | |
| Al-Sheraji et al. | Effects of Bifidobacterium longum BB536 on lipid profile and histopathological changes in hypercholesterolaemic rats | |
| US9884079B2 (en) | Biologically pure Lactobacillus mali strain and composition thereof for treating metabolic syndrome | |
| CN108077675A (en) | A kind of fruit drink for being used to prevent nonalcoholic fatty liver | |
| Anandharaj et al. | Corrigendum to “effects of probiotics, prebiotics, and synbiotics on hypercholesterolemia: A review” | |
| Makwana et al. | Effects of probiotic fermented milk on management of obesity studied in high-fat-diet induced obese rat model | |
| Chen et al. | Effects of Vigiis 101-LAB on a healthy population's gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study | |
| EP2407170B1 (en) | Prevention and treatment of obesity and metabolic diseases induced by obesity using microorganisms | |
| Ahmed et al. | Hypocholesterolaemic effect of probiotic yogurt enriched with barley β-glucan in rats fed on a high-cholesterol diet | |
| CN104955467A (en) | Lactobacillus rhamnosus strain for reducing body fat accumulation | |
| CN113207960B (en) | Bifidobacterium lactis MN-Gup fermented milk for improving obesity and preparation method thereof | |
| Georgieva et al. | Probiotics: past, present, and future challenges | |
| Galindev et al. | Anti-obesity effects of potential probiotic Lactobacillus strains isolated from Mongolian fermented dairy products in high-fat diet-induced obese rodent model | |
| Ibrahim et al. | Dietary modulation of gut microbiota by cultured products | |
| Ağagündüz et al. | The food-gut-health axis of dairy lactic acid bacteria | |
| Abdi-Moghadam et al. | Clinical Nutrition ESPEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |